- Home
- SNDX
as 11-26-2025 3:37pm EST
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 1.3B | IPO Year: | 2016 |
| Target Price: | $36.92 | AVG Volume (30 days): | 3.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.60 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.58 - $20.08 | Next Earning Date: | 11-03-2025 |
| Revenue: | $111,304,000 | Revenue Growth: | 595.65% |
| Revenue Growth (this year): | 636.61% | Revenue Growth (next year): | 114.95% |
Stock Insider Trading Activity of Syndax Pharmaceuticals Inc. (SNDX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Metzger Michael A | SNDX | Chief Executive Officer | Sep 8 '25 | Sell | $16.41 | 157,307 | $2,582,021.37 | 298,661 |
Latest Syndax Pharmaceuticals Inc. News
SNDX Breaking Stock News: Dive into SNDX Ticker-Specific Updates for Smart Investing
Simply Wall St.
9 days ago
Syndax Pharmaceuticals (SNDX): Assessing Value After Revuforj FDA Expansion and Revenue Surge
Insider Monkey
10 days ago
JPMorgan Reduces PT on Syndax Pharmaceuticals (SNDX) to $33, Maintains “Overweight” Rating
GuruFocus.com
a month ago
Syndax Pharmaceuticals Inc (SNDX) Q3 2025 Earnings Report Preview: What To Expect
GlobeNewswire
a month ago
Syndax Announces Participation in November Investor Conferences
GlobeNewswire
a month ago
Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025
Insider Monkey
2 months ago
Syndax’s Revumenib Added to NCCN AML Guidelines Ahead of October 25 FDA Decision
GlobeNewswire
2 months ago
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
The Fly
3 months ago
Synopsys downgraded, Oracle upgraded: Wall Street's top analyst calls
Compare SNDX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SNDX Syndax Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.